Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Esperion Therapeutics Inc (NasdaqNM:ESPR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
July 25Conference call: Esperion Therapeutics, Inc. Earnings (Q2 2001)
Location
3621 S. State Street, 695 KMS Place
Ann Arbor, MI 48108
Phone: (734) 332-0506
Fax: (734) 332-0516
Email: info@esperion.com
Employees (last reported count): 58
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 44%
·Over the last 6 months:
 · 5 insider sells; 83.0K shares
  (0.7% of insider shares)
·Institutional: 34% (60% of float)
(52 institutions)
·Net Inst. Buying: 2.52M shares (+22.40%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Esperion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of products for the treatment of cardiovascular and metabolic diseases. The Company has focused its initial drug development and discovery activities on a novel class of drugs to treat acute and chronic cardiovascular diseases. The Company intends to commercialize a novel class of drugs that focus on a new treatment approach the Company calls HDL Therapy, based upon its understanding of high density lipoprotein (HDL) function. Currently, the Company is working on five product candidates: LUV, AIM, RLT Peptide, ProApo A-1 and HDL Elevators, each designed to enhance the naturally occurring processes in the body that remove excess cholesterol from arterial walls. The Company initiated clinical trials with two of its product candidates in 2000 and expects to initiate clinical testing on additional product candidates in 2001.
More from Market Guide: Expanded Business Description

Financial Summary
Esperion Therapeutics, Inc. is a development stage pharmaceutical company engaging in research and development of pharmaceutical product candidates for cardiovascular disease. For the six months ended 6/30/01, revenues were unchanged at $0. Net loss applicable to Common fell 64% to $12.3 million. Results reflect the lack of any revenue generating drugs, the absence of $22.9 million in beneficial preferred stock conversion costs and higher interest income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

David Scheer, 48
Chairman
--  --  
Roger Newton, Ph.D., 50
Pres, CEO, Director
$280K--  
Timothy Mayleben, 40
VP-Fin., CFO
211K$238K
Charles Bisgaier, 47
VP, pharmacology
160K393K
Jean-Louis Dasseux, P.h.D., 42
VP, worldwide chemistry and technologies
179K79K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ESPRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 25-Apr-2001
$3.90 
Recent Price$7.01 
52-Week High
on 9-Nov-2000
$21.125
Daily Volume (3-month avg)96.7K
Daily Volume (10-day avg)80.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-56.9%
52-Week Change
relative to S&P500
-42.1%
Share-Related Items
Market Capitalization$181.9M
Shares Outstanding26.0M
Float14.5M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.17 
Earnings (ttm)-$1.43 
Earnings (mrq)-$0.24 
SalesN/A 
Cash (mrq)$2.34 
Valuation Ratios
Price/Book (mrq)3.23 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$30.3M
Income available to common (ttm)-$28.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-43.80%
Return on Equity (ttm)-51.63%
Financial Strength
Current Ratio (mrq)9.11 
Debt/Equity (mrq)0.11 
Total Cash (mrq)$60.7M
Short Interest
As of 8-Aug-2001
Shares Short130.0K
Percent of Float0.9%
Shares Short
(Prior Month)
236.0K
Short Ratio2.71 
Daily Volume48.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.